Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Pancreatic Cancer
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 75 years
- Gender
- Both males and females
Description
This study is an open, multicenter, Phase Ib/II clinical trial evaluating chimeric antigen receptor-modified autologous T cells targeting CLDN18.2 (CT041 autologous CAR T) in subjects with Claudin18.2 (CLDN18.2) expression-positive, advanced gastric/esophagogastric combination adenocarcinoma that ha...
This study is an open, multicenter, Phase Ib/II clinical trial evaluating chimeric antigen receptor-modified autologous T cells targeting CLDN18.2 (CT041 autologous CAR T) in subjects with Claudin18.2 (CLDN18.2) expression-positive, advanced gastric/esophagogastric combination adenocarcinoma that has failed at least second-line therapy and advanced pancreatic cancer that has failed at least first-line therapy. Cells, which will be referred to in the text as CT041) for effectiveness, safety and cellular metabolic kinetics.
Tracking Information
- NCT #
- NCT04581473
- Collaborators
- Beijing Cancer Hospital
- Fudan University
- Investigators
- Principal Investigator: Lin Shen, Professor Beijing Cancer Hospital Principal Investigator: Xianjun Yu, Professor Fudan University
Get Well Soon